Quoin gets FDA Fast Track for rare skin drug
Quoin Pharmaceuticals Ltd. (QNRX) announced that the U.S. FDA has granted Fast Track Designation to its investigational topical lotion QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment.
Rhea-AI Filing Summary
Quoin Pharmaceuticals Ltd. (QNRX) announced that the U.S. FDA has granted Fast Track Designation to its investigational topical lotion QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment. This is the second Fast Track Designation for QRX003, following an earlier designation for Netherton Syndrome.
The company expects to initiate a Phase 2/3 study in Peeling Skin Syndrome in the second half of 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe, with QRX003 applied twice daily over 48 weeks and an interim review at 24 weeks. Quoin is targeting potential approval of QRX003 for Peeling Skin Syndrome in 2028 and reports over 15 months of treatment in an investigator-led pediatric study with improved severity endpoints and no reported adverse events.
Positive
- FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome provides a formal pathway to more frequent FDA interactions, potential rolling review, and access to expedited programs, supporting development in a disease that currently has no approved treatment.
- Quoin plans a Phase 2/3 trial in Peeling Skin Syndrome starting in the second half of 2026 and is targeting potential approval in 2028, giving a clearer development timeline for this lead rare-disease asset.
- QRX003 already holds multiple regulatory incentives, including Orphan Drug, Rare Pediatric Disease, and Fast Track designations for Netherton Syndrome and additional Rare Pediatric Disease and Fast Track status for Peeling Skin Syndrome, which can support market exclusivity and potential priority review.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Fast Track Designation: Granted for QRX003 in Peeling Skin Syndrome
Planned Phase 2/3 enrollment: Up to 12 patients
Treatment duration: 48 weeks
+4 more
7 metrics
Fast Track Designation
Granted for QRX003 in Peeling Skin Syndrome
Announced on September 22, 2026 by Quoin Pharmaceuticals
Planned Phase 2/3 enrollment
Up to 12 patients
Pediatric and adult Peeling Skin Syndrome patients in the U.S. and Europe
Treatment duration
48 weeks
Twice-daily QRX003 application with interim data review at 24 weeks
Body surface area treated
Greater than 80%
Planned Phase 2/3 Peeling Skin Syndrome study design
Target approval year
2028
Quoin’s target for QRX003 approval in Peeling Skin Syndrome
QRX003 lotion concentration
4%
QRX003 lotion (4%) in Phase 2/3 trials for Netherton Syndrome
Ongoing pediatric treatment duration
Over 15 months
Investigator-led Peeling Skin Syndrome study with no reported adverse events
Key Terms
Fast Track Designation, Orphan Drug, Rare Pediatric Disease, Accelerated Approval, +2 more
6 terms
Fast Track Designation regulatory
"the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Orphan Drug regulatory
"QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
Rare Pediatric Disease regulatory
"QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track"
A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.
Accelerated Approval regulatory
"potential qualification for Accelerated Approval and Priority Review, if relevant"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
Priority Review regulatory
"potential qualification for Accelerated Approval and Priority Review, if relevant"
Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.
Modified Ichthyosis Area Severity Index (M-IASI) medical
"improvements across key objective severity endpoints, including the Modified Ichthyosis"
A modified ichthyosis area severity index (m-IAST) is a clinical scoring tool used to quantify how extensive and severe ichthyosis (a group of chronic skin disorders characterized by dry, scaly skin) is across the body. Like a standardized checklist that rates redness, scaling, thickness and the proportion of body affected and combines those ratings into a single score, it gives researchers and regulators a consistent way to measure whether a treatment changes the skin condition. For investors, m-IAST scores matter because they are often used as objective endpoints in clinical trials and regulatory filings to demonstrate a drug’s effectiveness or lack of effect.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Quoin Pharmaceuticals (QNRX) announce regarding QRX003 and the FDA?
Quoin announced that the U.S. FDA granted Fast Track Designation to QRX003 for treating Peeling Skin Syndrome, a rare genetic skin disease with no approved therapy. This status is intended to facilitate development and expedite review for conditions with significant unmet medical need.
What is the planned clinical trial design for QRX003 in Peeling Skin Syndrome at QNRX?
Quoin expects to start a Phase 2/3 study in the second half of 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe. QRX003 will be applied twice daily to more than 80% body surface area over 48 weeks, with an interim data review at 24 weeks.
When does Quoin Pharmaceuticals (QNRX) aim to obtain approval of QRX003 for Peeling Skin Syndrome?
Quoin states it is targeting approval in 2028 for QRX003 as a potential treatment for Peeling Skin Syndrome, subject to successful clinical trial results and regulatory review.
What prior regulatory milestones support QRX003 at Quoin Pharmaceuticals (QNRX)?
QRX003 has Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA for Netherton Syndrome, and Rare Pediatric Disease and Fast Track Designation for Peeling Skin Syndrome. It is being evaluated in Phase 2/3 whole-body trials for Netherton Syndrome.
What clinical evidence does Quoin (QNRX) report so far for QRX003 in Peeling Skin Syndrome?
An ongoing investigator-led pediatric study has shown improvements in severity endpoints such as M-IASI, IGA, pruritus, and CDLQI, with treatment continuing for over 15 months and no adverse events reported to date.
How does FDA Fast Track status potentially benefit Quoin Pharmaceuticals (QNRX)?
Fast Track status may allow more frequent FDA interactions, eligibility for rolling review of submissions, and potential qualification for Accelerated Approval and Priority Review if criteria are met, helping expedite development of QRX003 for serious unmet medical need.
AI-generated analysis. How Rhea-AI works. Not financial advice.
